Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see the volume maintaining. Hope some were able to take advantage advantage of the dip.
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $20
6:51 am ET July 1, 2022 (Benzinga) Print
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $18 to $20.
Latest Ratings for LXRX DateFirmActionFromTo
Jan 2021WedbushDowngradesOutperformNeutral Jan 2021JP MorganUpgradesUnderweightNeutral Dec 2020CitigroupUpgradesNeutralBuy
View More Analyst Ratings for LXRX
View the Latest Analyst Ratings
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
BooDog maintains that this is still an excellent swing play bio. At least till their next data set.
This could push back over $4 before the fun even begins.
LXRX daily
When only a few are even paying attention.
“We expect that the new joint guidelines issued this weekend by the three largest cardiology societies in the United States, along with the new guidelines issued last year by the European Society of Cardiology, will support the emerging adoption of SGLT2 inhibitors as a first line treatment standard across heart failure,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer at Lexicon. “We believe that sotagliflozin’s unique mechanism offers opportunities for differentiation within the class, supported by the results from the SOLOIST-WHF study referenced in the guidelines as well as from the SCORED study, additional analyses from which were presented at the American College of Cardiology 71st Annual Scientific Sessions this weekend.”
https://marketwirenews.com/news-releases/lexicon-welcomes-new-guidelines-for-the-management-o-7753296108030739.html
Time to move out of the shadows.
Very interesting intraday recovery. News after close? Early next week?
Hmmmmmmmmmm
What do I dislike more than bleeders? Wash sales. Triggering a S/L, as this has done multiple times, is the wash sale that won't let me take advantage of the tax break at the end of the year.
Just need to see a solid bottom at this point, and maybe even set up for a pinch.
Might be my last add here, $3.58. Gap from August filled. See if this holds the 3.58.
If anyone's looking, take a look at the Ichimoku charts as well. I see some decent basing potential. Otherwise the charts really aren't that appetizing. Until something happens. With low volume days it's easily manipulated.
Don't let the price action fool you, play wisely of course but if they do get the nod from the FDA, there'll be plenty left in the dust.
https://ih.advfn.com/p.php?pid=nmona&article=86915286
imo
Also,, note the low volume manipulation.
LXRX 4.99 Golden Cross in progress.
LXRX daily
See where the dip bottoms out. Took some earlier @ 5.06. Letting it set up before I take more.
GLTA
Should have remembered what earnings do in this sector. Did take a chunk of 4.94's though.
Don't even look at the chart. If my glance is right I'll be getting more around the 4.70's or lower.
Let's see their catalyst for sotagliflozin before Jan 1st take this on up to $14 or better. Yeah, I like that idea much better.
For entertainment use only? eh, just so you know, I do own shares. Just a few.
Thanks Chupacabra Gigante!!! Yes, looking very good here. This has been one of my best long term holdings.
200 DMA 5.32, 50 DMA 4.94. With a 20 DMA of 5.42 pulling up the 50 & 20 about $0.10 a week we may see this pull a golden cross around Thanksgiving.
LXRX daily
Boo Dog
Congrats for coming across this opportunity, I see a five fold move in this over the next 14 months. Haven't lurked on this board for years,just wanted to see if anyone has caught onto this opportunity.
Best of luck.
This just may get interesting. Let's see if they can speed up the 50 dma to make the golden cross. To do it this would need to pass 6.33 resistance in a hurry. Not saying it'll happen but I see the potential.
LXRX daily
50 dma is sitting at 4.74
13 @ 5.56
20dma already crossed over the 200.
Small bite here at $5. Next buy around 4.60's. If it gets there. or at $4 if it looks to go there.
Who knows!!!!?
Did take a few off 6.23. Looking forward to this going over $10 eventually.
My opinion of course. This gets a decent reset I'll get my shares back.
Form 3's building their positions. I'm thinking I'm not the only one thinking this'll be breaking out in the near term.
5.86 high today likely from Cramer's mention. I'm not selling anymore.
Cramer said 5.90 lol. See if it gets there.
https://realmoney.thestreet.com/investing/take-a-pass-on-lexicon-pharmaceuticals-for-now-15790582?puc=yahoo&cm_ven=YAHOO
Big things are happening for LXRX imo. Yes, revenue from licensing and royalties looks like. Their day is very close on the horizon.
https://www.lexpharma.com/pipeline
But they have not one piece sold in Europe, Lexicon is waiting for??
Therefore SP flat
This is excellent news. Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
August 30 2021 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) welcomes the new recommendation by the European Society of Cardiology (ESC) to add SGLT inhibitors as part of the standard of care for the prevention and treatment of heart failure (HF). SGLT inhibitors have been given a Class IA recommendation-- the strongest endorsement-- in updated clinical practice guidelines released by the ESC Heart Failure working group in the EU at its annual meeting, the ESC Congress 2021 - The Digital Experience.
Specifically, the guidelines recommend the following for the primary prevention of HF in patients with risk factors for its development:
“SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with diabetes at high risk of cardiovascular (CV) disease or with CV disease in order to prevent HF hospitalizations.”
The guidelines recommend the following for the treatment of patients with HF and diabetes or for the treatment of diabetes in HF:
“SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, sotagliflozin) are recommended in patients with type 2 diabetes mellitus (T2DM) at risk of CV events to reduce hospitalizations for HF, major CV events, end-stage renal dysfunction, and CV death.”
“SGLT2 inhibitors (dapagliflozin, empagliflozin, and sotagliflozin) are recommended in patients with T2DM and heart failure with reduced ejection fraction (HFrEF) to reduce hospitalizations for HF and CV death.”
The guidelines also addressed worsening heart failure, noting:
“The combined SGLT-1 and 2 inhibitor, sotagliflozin, has also been studied in patients with diabetes who were hospitalized with HF. The drug reduced CV death and hospitalization for HF.”
“Safety and better outcome have also been recently shown in a prospective randomized trial with sotagliflozin in diabetic patients hospitalized for HF, irrespective of their left ventricular ejection fraction (LVEF).”
“It is quite rare for an investigational drug to be listed in the guidelines prior to regulatory approval and we do not take the trust and confidence that ESC has placed in sotagliflozin lightly,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer at Lexicon. “We know patients with heart failure suffer reduced quality of life and remain at high risk of hospitalization or death, and these new guidelines are a strong call to action to ensure patients receive the most effective therapies for acute and chronic heart failure. We continue to work diligently for these patients and plan to submit a New Drug Application with the U.S. Food and Drug Administration later this year for its review of sotagliflozin, as a therapy for people suffering from heart failure and living with type 2 diabetes.”
The full 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure can be found at escardio.org.
About Sotagliflozin
Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Sotagliflozin is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy, but has not yet been commercially launched. Sotagliflozin is not approved for use in any other indications, including heart failure.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s clinical development of and regulatory filings for sotagliflozin and the therapeutic and commercial potential of sotagliflozin. This press release also contains forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Inquiries:
Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com
Back over $4. Looking pretty imo. Low only went to 3.31.
4.08
ACTIVE POSITIONS HOLDERS SHARES
Increased Positions 64 5,441,175
Decreased Positions 49 4,990,352
Held Positions 19 111,261,581
Total Institutional Shares 132 121,693,108
https://www.nasdaq.com/market-activity/stocks/lxrx/institutional-holdings
Lexicon Pharmaceuticals (NASDAQ:LXRX) - P/E: 7.72
Lexicon Pharmaceuticals has reported Q2 earnings per share at -0.13, which has increased by 13.33% compared to Q1, which was -0.15.
Cooper Companies has reported Q2 earn
Really nothing to get excited about.
For me, it's about the volatility. It'll be a bit longer for their major catalysts but I'll be keeping a core.
Best to all the lurkers out there!!!
Possibly see $3 even soon.
Been munching some of these dips.
LXRX setting up very nicely. Range 3.31 - 3.47
LXRX
Added 3.98 today.
Mine. I've been waiting forever for this pull back. Back in for a nibble here 4.15. Will he stacking up the chips as we set a bottom.
Many predict 15-20 relatively short term if they announce a partner soon.
Long term it could go much higher.
Maybe a pullback today after the 100% gain yesterday, not surprising.
* * $LXRX Video Chart 01-14-2021 * *
Link to Video - click here to watch the technical chart video
Yes a very good day, I am keeping my shares for now.
LXRX NEWS Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
https://finance.yahoo.com/news/lexicon-pharmaceuticals-provides-regulatory-sotagliflozin-130000096.html
Made a few nice round trips on this puppy!! Keeping a handful for sure.
Skimmed a few off @ 3.60. Looks like this may keep on rolling but locked in some green none the less.
Looking good $LXRX!!!
LXRX Golden cross alert
https://finance.yahoo.com/news/moving-average-crossover-alert-lexicon-111111555.html?guccounter=1
Even though it happened back on the 24th it's still worth noting.
Gosh. What is this
?? glad I'm not the only one
Took a few more under $3. Why not. Seems like I've been doing some Christmas shopping all over the place!
Here's the science with AC Bioscience. They just may move this along smartly.
https://www.ac-bioscience.com/pipeline#ja-section-545
https://finance.yahoo.com/news/lexicon-pharmaceuticals-enters-data-collaboration-210500959.html
Lexicon Pharmaceuticals Enters Data Collaboration With AC Bioscience
4:05 pm ET December 16, 2020 (Globe Newswire) Print
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has entered a collaboration enabling the use by AC Bioscience LTD of preclinical and clinical data for LX2931 without granting any right or license under any of Lexicon's patent rights for the compound. LX2931 is a small molecule sphingosine-1-phosphate (S1P) lyase inhibitor that is currently not in active development at Lexicon.
"In line with our realignment around the rapid development of the LX9211 program, we continue to evaluate our pipeline and determine the most effective way to advance our broad library of compounds and targets," said Praveen Tyle, Ph.D., executive vice president of research and development. "We are pleased to collaborate with AC Bioscience to accelerate their efforts around S1P and look forward to learning additional information about this potentially interesting pathway."
Under the terms of the agreement, Lexicon will receive an upfront payment and is eligible to receive milestone payments totaling up to $5.3 million in the aggregate.
About Lexicon Pharmaceuticals
Followers
|
55
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
774
|
Created
|
02/27/05
|
Type
|
Free
|
Moderators |
Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies
THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.
In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.
The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.
“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |